|
Market Cap (5-Jul) $86,511,600 (718th) |
Close (30-Jun) $0.63 |
Volume (30-Jun) 55,179 |
Shortsold (19-Jun) 190,561 (0.07%) (455th) |
|
52w High $0.57 |
52w Low $0.275 |
P/E - |
EPS -0.09 |
RCE released this announcement to the ASX on 4 May 2021, 8:19. The announcement is marked as price sensitive, and is 5 page(s) in length and 883.37kb in size.
You can view all announcements from RCE and see how they appear on a price chart on the announcements page.
At the date of this announcement, RCE was 0.032% short sold according to ASIC data. It was ranked the 519th most shorted stock on the ASX. It is now ranked as the 455th most shorted stock on the ASX with 0.066% of total shares short sold as of the latest reported data (19 June 2025).
| Other Recent Announcements from RCE | |
|---|---|
| Ethics Approval for Phase I/II UTI Trial Expansion | 29 June 2023, 13:49 |
| Change of Director's Interest Notice - J Graham | 26 June 2023, 15:58 |
| DFI Clinical Trial Outpatient Nurses Appointed | 29 May 2023, 10:54 |
| Positive Data on RECCE 327 Against All Six ESKAPE Pathogens | 4 May 2021, 8:19 |
| Appendix 4C and Activity Report | 27 April 2021, 10:28 |
| RECCE 327 Registered for Topical Burns Study in Humans | 15 April 2021, 12:34 |
| Positive Sinusitis Patient Update - Special Access Scheme | 7 April 2021, 10:09 |
You must be logged in to post a reply.
Recce Pharmaceuticals Ltd 